BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 12163455)

  • 1. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity.
    Saegusa K; Ishimaru N; Yanagi K; Arakaki R; Ogawa K; Saito I; Katunuma N; Hayashi Y
    J Clin Invest; 2002 Aug; 110(3):361-9. PubMed ID: 12163455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cathepsin S activity regulates antigen presentation and immunity.
    Riese RJ; Mitchell RN; Villadangos JA; Shi GP; Palmer JT; Karp ER; De Sanctis GT; Ploegh HL; Chapman HA
    J Clin Invest; 1998 Jun; 101(11):2351-63. PubMed ID: 9616206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages.
    Shi GP; Bryant RA; Riese R; Verhelst S; Driessen C; Li Z; Bromme D; Ploegh HL; Chapman HA
    J Exp Med; 2000 Apr; 191(7):1177-86. PubMed ID: 10748235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and induction of autoimmune exocrinopathy is dependent on pathogenic autoantigen cleavage in murine Sjögren's syndrome.
    Saegusa K; Ishimaru N; Yanagi K; Mishima K; Arakaki R; Suda T; Saito I; Hayashi Y
    J Immunol; 2002 Jul; 169(2):1050-7. PubMed ID: 12097413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantigens and Sjögren syndrome.
    Toda I
    Cornea; 2002 Mar; 21(2 Suppl 1):S13-6. PubMed ID: 11995803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-120-kDa alpha-fodrin immune response with Th1-cytokine profile in the NOD mouse model of Sjögren's syndrome.
    Yanagi K; Ishimaru N; Haneji N; Saegusa K; Saito I; Hayashi Y
    Eur J Immunol; 1998 Oct; 28(10):3336-45. PubMed ID: 9808203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo.
    Beers C; Burich A; Kleijmeer MJ; Griffith JM; Wong P; Rudensky AY
    J Immunol; 2005 Feb; 174(3):1205-12. PubMed ID: 15661874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-γ treatment in vitro elicits some of the changes in cathepsin S and antigen presentation characteristic of lacrimal glands and corneas from the NOD mouse model of Sjögren's Syndrome.
    Meng Z; Klinngam W; Edman MC; Hamm-Alvarez SF
    PLoS One; 2017; 12(9):e0184781. PubMed ID: 28902875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantigen-specific CD4+CD28low T cell subset prevents autoimmune exocrinopathy in murine Sjögren's syndrome.
    Saegusa K; Ishimaru N; Yanagi K; Haneji N; Nishino M; Azuma M; Saito I; Hayashi Y
    J Immunol; 2000 Aug; 165(4):2251-7. PubMed ID: 10925313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal administration of alpha-fodrin inhibits experimental Sjögren's syndrome autoimmunity.
    He J; Zhao J; Li Z
    Arthritis Res Ther; 2008; 10(2):R44. PubMed ID: 18419828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypothesis for autoantigen presentation and T cell activation.
    Mircheff AK; Gierow JP; Wood RL; Akashi RH; Hofman FM
    Adv Exp Med Biol; 1994; 350():651-4. PubMed ID: 8030550
    [No Abstract]   [Full Text] [Related]  

  • 12. Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice.
    Maehr R; Hang HC; Mintern JD; Kim YM; Cuvillier A; Nishimura M; Yamada K; Shirahama-Noda K; Hara-Nishimura I; Ploegh HL
    J Immunol; 2005 Jun; 174(11):7066-74. PubMed ID: 15905550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors.
    Katunuma N; Matsunaga Y; Himeno K; Hayashi Y
    Biol Chem; 2003 Jun; 384(6):883-90. PubMed ID: 12887055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MHC class II molecules, cathepsins, and La/SSB proteins in lacrimal acinar cell endomembranes.
    Yang T; Zeng H; Zhang J; Okamoto CT; Warren DW; Wood RL; Bachmann M; Mircheff AK
    Am J Physiol; 1999 Nov; 277(5):C994-C1007. PubMed ID: 10564093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of alpha-fodrin as a candidate autoantigen in primary Sjögren's syndrome.
    Haneji N; Nakamura T; Takio K; Yanagi K; Higashiyama H; Saito I; Noji S; Sugino H; Hayashi Y
    Science; 1997 Apr; 276(5312):604-7. PubMed ID: 9110981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of neonatal tolerance induced in an animal model for primary Sjögren's syndrome by intravenous administration of autoantigen.
    Saegusa K; Ishimaru N; Haneji N; Yanagi K; Yoneda T; Saito I; Hayashi Y
    Scand J Immunol; 2000 Sep; 52(3):264-70. PubMed ID: 10972902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of caspase cascade on the development of primary Sjögren's syndrome.
    Hayashi Y; Arakaki R; Ishimaru N
    J Med Invest; 2003 Feb; 50(1-2):32-8. PubMed ID: 12630566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel fragments of the Sjögren's syndrome autoantigens alpha-fodrin and type 3 muscarinic acetylcholine receptor generated during cytotoxic lymphocyte granule-induced cell death.
    Nagaraju K; Cox A; Casciola-Rosen L; Rosen A
    Arthritis Rheum; 2001 Oct; 44(10):2376-86. PubMed ID: 11665980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible involvement of EBV-mediated alpha-fodrin cleavage for organ-specific autoantigen in Sjogren's syndrome.
    Inoue H; Tsubota K; Ono M; Kizu Y; Mizuno F; Takada K; Yamada K; Yanagi K; Hayashi Y; Saito I
    J Immunol; 2001 May; 166(9):5801-9. PubMed ID: 11313424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both cathepsin B and cathepsin D are necessary for processing of ovalbumin as well as for degradation of class II MHC invariant chain.
    Mizuochi T; Yee ST; Kasai M; Kakiuchi T; Muno D; Kominami E
    Immunol Lett; 1994 Dec; 43(3):189-93. PubMed ID: 7721331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.